跳转至内容
Merck

E3652

Sigma-Aldrich

Epoxomicin

≥95% (HPLC), solid

别名:

N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide

登录查看公司和协议定价


About This Item

MDL號碼:
分類程式碼代碼:
12352202
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥95% (HPLC)

形狀

solid

儲存溫度

−20°C

SMILES 字串

CC[C@H](C)[C@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

InChI

1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1

InChI 密鑰

DOGIDQKFVLKMLQ-JTHVHQAWSA-N

一般說明

Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketone derived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated from Actinomyces sp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor.

應用

Epoxomicin has been used:
  • as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cells
  • as a proteasome inhibitor in mammary epithelial MCF-10A cells
  • as a proteasome inhibitor in chymotryptic assay in cardiomyocytes

生化/生理作用

Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent.
Epoxomicin, a natural product isolated from Actinomyces sp., is a cell-permeable, potent, selective and irreversible proteasome inhibitor.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Meng L, et al.
Proceedings of the National Academy of Sciences of the USA, 96(18), 10403-10408 (1999)
L Meng et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(18), 10403-10408 (1999-09-01)
The proteasome regulates cellular processes as diverse as cell cycle progression and NF-kappaB activation. In this study, we show that the potent antitumor natural product epoxomicin specifically targets the proteasome. Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epoxomicin
Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model
Yu X, et al.
Journal of Molecular Neuroscience, 47(2), 219-233 (2012)
Kyung Bo Kim et al.
Natural product reports, 30(5), 600-604 (2013-04-12)
The initial enthusiasm following the discovery of a pharmacologically active natural product is often fleeting due to the poor prospects for its ultimate clinical application. Despite this, the ever-changing landscape of modern biology has a constant need for molecular probes
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses
Schwarz K, et al.
Journal of Immunology, 164(12), 6147-6157 (2000)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门